Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 3
2016 5
2017 8
2018 6
2019 1
2020 13
2021 11
2022 5
2023 3
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Cirillo A, Marinelli D, Romeo U, Messineo D, De Felice F, De Vincentiis M, Valentini V, Mezi S, Valentini F, Vivona L, Chiavassa A, Cerbelli B, Santini D, Bossi P, Polimeni A, Marchetti P, Botticelli A. Cirillo A, et al. Among authors: marinelli d. BMC Cancer. 2024 Apr 17;24(1):487. doi: 10.1186/s12885-024-12249-y. BMC Cancer. 2024. PMID: 38632499 Free PMC article. No abstract available.
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Cirillo A, Marinelli D, Romeo U, Messineo D, De Felice F, De Vincentiis M, Valentini V, Mezi S, Valentini F, Vivona L, Chiavassa A, Cerbelli B, Santini D, Bossi P, Polimeni A, Marchetti P, Botticelli A. Cirillo A, et al. Among authors: marinelli d. BMC Cancer. 2024 Apr 8;24(1):430. doi: 10.1186/s12885-024-12155-3. BMC Cancer. 2024. PMID: 38589857 Free PMC article.
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Botticelli A, Caputo R, Scagnoli S, Pisegna S, De Laurentiis M, Curigliano G, Lambertini M, Pantano F, Palazzo A, Paris I, Vernieri C, Tedesco B, Giampaglia M, Palleschi M, Ballatore Z, Alesini D, D'Auria G, Fabbri A, Rossi L, Verrazzo A, Scafetta R, Marinelli D, Sposetti C, Barberi V, Strigari L, Marchetti P, Santini D, Fabi A. Botticelli A, et al. Among authors: marinelli d. Oncologist. 2024 Apr 4;29(4):303-310. doi: 10.1093/oncolo/oyad308. Oncologist. 2024. PMID: 37995313 Free PMC article.
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials.
Marinelli D, Gallina FT, Pannunzio S, Di Civita MA, Torchia A, Giusti R, Gelibter AJ, Roberto M, Verrico M, Melis E, Tajè R, Cecere FL, Landi L, Nisticò P, Porciello N, Occhipinti M, Brambilla M, Forde PM, Liu SV, Botticelli A, Novello S, Ciliberto G, Cortesi E, Facciolo F, Cappuzzo F, Santini D. Marinelli D, et al. Crit Rev Oncol Hematol. 2023 Dec;192:104190. doi: 10.1016/j.critrevonc.2023.104190. Epub 2023 Oct 21. Crit Rev Oncol Hematol. 2023. PMID: 37871779 Free article.
54 results